RE: Maybe next week27 Feb 2026 12:40
Example in full:
Examples
The FDA approved benzgalantamine (Zunveyl; Alpha Cognition Inc), a novel oral therapy, for the treatment of Alzheimer disease, on July 26, 2024. The manufacturer submitted the NDA on September 27, 2023, with an original PDUFA date of July 27, 2024—10 months from submission.